Goutifad 80 mg 20 tablets

Tradename

Goutifade

Composition

Each tablet contains:

Febuxostat 80 mg

Auxiliary components: lactose monohydrate, hyprolose, microcrystalline cellulose (Avicel PH 101), microcrystalline cellulose (Avicel PH 102), croscarmellose sodium, magnesium stearate, water colloidal silicon dioxide.

Properties

Selective non-purine xanthine oxidase inhibitor, 2-arylthiazole derivative. The enzyme xanthine oxidase catalyzes two stages of purine metabolism: the oxidation of hypoxanthine to xanthine, and then the oxidation of xanthine to uric acid. As a result of febuxostat selective inhibition of xanthine oxidase (oxidized and reduced forms), the concentration of uric acid in the blood serum decreases. The in vitro inhibition constant is less than 1 nM. At therapeutic concentratiofebuxostat does not inhibit other enzymes involved in the metabolism of purines or pyrimidines, such as guanine deaminase, hypoxanthine guanine phosphoribosyltransferase, orotatephosphoribosyltransferase, orotidine monophosphate decarboxylase or purine nucleosylase. The use of febuxostat leads to a more effective reduction in the concentration of uric acid and maintenance of its level in the blood serum compared with allopurinol. There were no clinically significant differences in the degree of decrease in the concentration of uric acid in the blood serum compared with healthy volunteers (the decrease in the concentration of uric acid in the group of patients with normal renal function is 58%, in the group with severe renal failure — 55%). When using febuxostat for the prevention and treatment of tumor disintegration syndrome, a more intense and rapid decrease in serum uric acid concentration was observed compared with allopurinol. There were no clinically significant differences in the degree of decrease in the concentration of uric acid in the blood serum compared with healthy volunteers (the decrease in the concentration of uric acid in the group of patients with normal renal function is 58%, in the group with severe renal failure 55%). When using febuxostat for the prevention and treatment of tumor disintegration syndrome, a more intense and rapid decrease in serum uric acid concentration was observed compared with allopurinol. There were no clinically significant differences in the degree of decrease in the concentration of uric acid in the blood serum compared with healthy volunteers (the decrease in the concentration of uric acid in the group of patients with normal renal function is 58%, in the group with severe renal failure — 55%). When using febuxostat for the prevention and treatment of tumor disintegration syndrome, a more intense and rapid decrease in serum uric acid concentration was observed compared with allopurinol.

Indications

Treatment of chronic hyperuricemia in conditions accompanied by the deposition of urate crystals (in the presence of tophus and / or gouty arthritis, including a history).

Treatment and prevention of hyperuricemia in adult patients during cytostatic therapy of hemoblastosis with a moderate to high risk of tumor disintegration syndrome (only for a dose of 120 mg).

Method of administration and dosage:

Contraindications

Pregnancy, breastfeeding period; children up to age 18; hypersensitivity to febuxostat.

Precautions:

Use with caution in the following diseases and conditions: severe renal failure (CC ml / min) (efficacy and safety have not been studied enough); liver failure; a history of serious allergic reactions (hypersensitivity reactions); Ischemic heart disease; congestive heart failure; thyroid disease; simultaneous use with mercaptopurine / azathioprine (it is possible to increase the concentration of these substan in the blood plasma and increase their toxic conditions after organ transplantation

Side effects

From the nervous system: often — headache;

From the side of metabolism: often — gout attacks; infrequently — diabetes mellitus, hyperlipidemia, decreased appetite, weight

gain, increased concentration of urea in blood plasma;